Pembrolizumab with sacituzumab govitecan instead of chemotherapy led to improved progression-free survival in PD-L1-postive ...

Using the ‘golden key’ to identify suitable patients, the results from the trial indicate that deaths could be cut by a third ...

The treatment could also delay the need for gruelling chemotherapy, according to the trial. | ITV National News ...

The lead author said the study also showed the inavolisib-based therapy "more than doubled the time before their cancer progressed or worsened".

A 14-gene molecular assay could help predict which patients with early-stage non-small cell lung cancer will benefit from ...

A new three-drug combination could help women with a common form of aggressive breast cancer live longer, research suggests - ...

On World No Tobacco Day, Imperial Tobacco Canada (Imperial) is calling on government, health advocates, and all Canadians to embrace?harm reduction as a key strategy to achieve a smokeless Canada in ...

A “breakthrough” new three-drug combination offers hope for women battling an aggressive form of breast cancer, potentially ...

AstraZeneca and Daiichi Sankyo’s drug extended survival by 30% compared to a widely used regimen, further establishing its ...

CHICAGO -- Combining pembrolizumab (Keytruda) with sacituzumab govitecan (SG, Trodelvy) instead of chemotherapy as first-line ...

A molecular test identified patients with high-risk early lung cancer who significantly benefitted from adjuvant chemotherapy ...